Monopar Therapeutics Ownership
| MNPR Stock | USD 40.00 4.74 10.59% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 4 M | Current Value 4 M | Avarage Shares Outstanding 2.6 M | Quarterly Volatility 640.5 K |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Monopar |
Monopar Stock Ownership Analysis
About 37.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.98. Monopar Therapeutics had not issued any dividends in recent years. The entity had 1:5 split on the 13th of August 2024. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. To find out more about Monopar Therapeutics contact MBA MD at 847 388 0349 or learn more at https://www.monopartx.com.Besides selling stocks to institutional investors, Monopar Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Monopar Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Monopar Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Monopar Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Monopar Therapeutics Insider Trades History
About 37.0% of Monopar Therapeutics are currently held by insiders. Unlike Monopar Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Monopar Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Monopar Therapeutics' insider trades
Monopar Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Monopar Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Monopar Therapeutics backward and forwards among themselves. Monopar Therapeutics' institutional investor refers to the entity that pools money to purchase Monopar Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-12-31 | 2 K | Tower Research Capital Llc | 2024-12-31 | 696 | Goss Wealth Management Llc | 2024-12-31 | 600 | Wells Fargo & Co | 2024-12-31 | 250 | Sbi Securities Co Ltd | 2024-12-31 | 100.0 | Bank Of America Corp | 2024-12-31 | 28.0 | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 16.0 | Gerber Llc | 2024-09-30 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Hhg Plc | 2024-12-31 | 1 M | Adage Capital Partners Gp Llc | 2024-12-31 | 599.2 K |
Monopar Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monopar Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monopar Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Monopar Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Monopar Therapeutics Outstanding Bonds
Monopar Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Monopar Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Monopar bonds can be classified according to their maturity, which is the date when Monopar Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US610202BR34 Corp BondUS610202BR34 | View | |
| US610202BP77 Corp BondUS610202BP77 | View |
Monopar Therapeutics Corporate Filings
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 6th of March 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 3rd of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Monopar Stock
Moving against Monopar Stock
| 0.55 | CDIO | Cardio Diagnostics | PairCorr |
| 0.53 | CRNX | Crinetics Pharmaceuticals | PairCorr |
| 0.4 | ASMB | Assembly Biosciences Earnings Call This Week | PairCorr |
| 0.33 | SCLX | Scilex Holding | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.